Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report
Abstract Given the rarity of RAD51C mutations, the risk and treatment of metachronous breast cancer after the diagnosis of ovarian cancer in RAD51C mutation carriers is not clear, especially for those who have received PARPi treatment. We report the case of a 65-year-old woman diagnosed with stage I...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | Hereditary Cancer in Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13053-024-00274-8 |
| _version_ | 1797273011781369856 |
|---|---|
| author | Hua Yuan Rong Zhang Ning Li Hongwen Yao |
| author_facet | Hua Yuan Rong Zhang Ning Li Hongwen Yao |
| author_sort | Hua Yuan |
| collection | DOAJ |
| description | Abstract Given the rarity of RAD51C mutations, the risk and treatment of metachronous breast cancer after the diagnosis of ovarian cancer in RAD51C mutation carriers is not clear, especially for those who have received PARPi treatment. We report the case of a 65-year-old woman diagnosed with stage IIIC high-grade serous primary fallopian tube cancer. The patient had no family history of breast or ovarian cancer. The patient received three cycles of neoadjuvant chemotherapy with paclitaxel and carboplatin and achieved a complete response. After interval debulking surgery, the patient received three cycles of adjuvant chemotherapy. Collection and extraction of saliva DNA for next-generation sequencing identified a RAD51C mutation c.838-2 A > G. The patient received niraparib as front-line maintenance treatment. After 36 months of niraparib treatment, the patient had grade II invasive ductal carcinoma of the left breast that was positive for estrogen receptor (90%) and Ki-67 (30%) and negative for progesterone receptor and human epidermal growth factor receptor 2. Computed tomography revealed the absence of distant metastases. Modified radical mastectomy and axillary lymph node dissection were then performed. The final pathological report of the breast showed a 1.8 cm Bloom-Richardson grade II invasive ductal carcinoma in the left breast with axillary lymph node metastasis (1/21). Finally, the breast cancer was stage IIA, pT1cN1M0. The metachronous breast cancer in this case may be the first report of second primary cancer in fallopian tube cancer patient harboring a RAD51C mutation during niraparib treatment. Further studies are required to determine optimal treatment. |
| first_indexed | 2024-03-07T14:37:31Z |
| format | Article |
| id | doaj.art-1637f5f96a5c455187dd8ba72fac735a |
| institution | Directory Open Access Journal |
| issn | 1897-4287 |
| language | English |
| last_indexed | 2024-03-07T14:37:31Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Hereditary Cancer in Clinical Practice |
| spelling | doaj.art-1637f5f96a5c455187dd8ba72fac735a2024-03-05T20:32:09ZengBMCHereditary Cancer in Clinical Practice1897-42872024-02-012211610.1186/s13053-024-00274-8Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case reportHua Yuan0Rong Zhang1Ning Li2Hongwen Yao3Department of Gynecologic Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Gynecologic Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Gynecologic Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Gynecologic Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Given the rarity of RAD51C mutations, the risk and treatment of metachronous breast cancer after the diagnosis of ovarian cancer in RAD51C mutation carriers is not clear, especially for those who have received PARPi treatment. We report the case of a 65-year-old woman diagnosed with stage IIIC high-grade serous primary fallopian tube cancer. The patient had no family history of breast or ovarian cancer. The patient received three cycles of neoadjuvant chemotherapy with paclitaxel and carboplatin and achieved a complete response. After interval debulking surgery, the patient received three cycles of adjuvant chemotherapy. Collection and extraction of saliva DNA for next-generation sequencing identified a RAD51C mutation c.838-2 A > G. The patient received niraparib as front-line maintenance treatment. After 36 months of niraparib treatment, the patient had grade II invasive ductal carcinoma of the left breast that was positive for estrogen receptor (90%) and Ki-67 (30%) and negative for progesterone receptor and human epidermal growth factor receptor 2. Computed tomography revealed the absence of distant metastases. Modified radical mastectomy and axillary lymph node dissection were then performed. The final pathological report of the breast showed a 1.8 cm Bloom-Richardson grade II invasive ductal carcinoma in the left breast with axillary lymph node metastasis (1/21). Finally, the breast cancer was stage IIA, pT1cN1M0. The metachronous breast cancer in this case may be the first report of second primary cancer in fallopian tube cancer patient harboring a RAD51C mutation during niraparib treatment. Further studies are required to determine optimal treatment.https://doi.org/10.1186/s13053-024-00274-8Primary breast cancerPrimary fallopian tube cancerRAD51C mutationNiraparib case report |
| spellingShingle | Hua Yuan Rong Zhang Ning Li Hongwen Yao Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report Hereditary Cancer in Clinical Practice Primary breast cancer Primary fallopian tube cancer RAD51C mutation Niraparib case report |
| title | Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report |
| title_full | Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report |
| title_fullStr | Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report |
| title_full_unstemmed | Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report |
| title_short | Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report |
| title_sort | primary fallopian tube cancer followed by primary breast cancer in rad51c mutation carrier treated with niraparib as first line maintenance therapy a case report |
| topic | Primary breast cancer Primary fallopian tube cancer RAD51C mutation Niraparib case report |
| url | https://doi.org/10.1186/s13053-024-00274-8 |
| work_keys_str_mv | AT huayuan primaryfallopiantubecancerfollowedbyprimarybreastcancerinrad51cmutationcarriertreatedwithniraparibasfirstlinemaintenancetherapyacasereport AT rongzhang primaryfallopiantubecancerfollowedbyprimarybreastcancerinrad51cmutationcarriertreatedwithniraparibasfirstlinemaintenancetherapyacasereport AT ningli primaryfallopiantubecancerfollowedbyprimarybreastcancerinrad51cmutationcarriertreatedwithniraparibasfirstlinemaintenancetherapyacasereport AT hongwenyao primaryfallopiantubecancerfollowedbyprimarybreastcancerinrad51cmutationcarriertreatedwithniraparibasfirstlinemaintenancetherapyacasereport |